TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19667506
Drug: Sulfonylureas, repaglinide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylureas, repaglinide, metformin, acarbose, thiazolidinediones
Study: 8979780
Drug: OAM (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAM (omeprazole 20 mg daily, amoxycillin 500 mg tid, metronidazole 400 mg tid)
Study: 8979780
Drug: RAM (ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAM (ranitidine 600 mg bd, amoxycillin 500 mg tid, metronidazole 400 mg tid)
Study: 8979780
Drug: OC (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC (omeprazole 20 mg daily, clarithromycin 500 mg tid)
Study: 8979780
Drug: OP (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: OP (omeprazole 20 mg daily and placebo)
Study: 1279170
Drug: Intravenous iloprost
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous iloprost (0.5-2.0 ng/kg/min)
Study: 27243567
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Processing Therapy‐Cognitive Only Version
Study: 27243567
Drug: Group Present‐Centered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Present‐Centered Therapy
Study: 27243567
Drug: Participants who
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who no longer met criteria for PTSD following treatment
Study: 24684977
Drug: Sleep medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep medication use
Study: 15705230
Drug: Lyc‐o‐Mato((R)) drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyc‐o‐Mato((R)) drink (250 ml daily providing about 6 mg lycopene, 4 mg phytoene, 3 mg phytofluene, 1 mg beta‐carotene, and 1.8 mg alpha‐tocopherol)
Study: 10369848
Drug: Sotalol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (160 to 320 mg per day)
Study: 7725845
Drug: Calcitonin (CT)
DrugBank: Calcitonin porcine (DB13189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin (CT) treatment with 100 IU and 250 mg calcium 3 times a week
Study: 7725845
Drug: Routine thalassemia
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine thalassemia therapy (Control)
Study: 2202804
Drug: Diazepam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.5 mg/kg, then 0.20 mg/kg, every 12 hours)
Study: 7032343
Drug: Budesonide nasal
Normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide nasal spray 200 micrograms b.i.d.
Study: 30326770
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (iOT)
Study: 24819432
Drug: Multimodal physiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal physiotherapy program (MPP) twice a week (G2: n=58)
Study: 23969334
Drug: Hinokitiol-containing gel
Normalized name: sodium hinokitiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hinokitiol-containing gel
Study: 23969334
Drug: Control gel
Normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL GEL [Walgreens Acne Control Gel]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control gel (not containing hinokitiol)
Study: 19273704
Drug: Doxorubicin 75
Normalized name: DOXOrubicin 75 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 75 mg/m² every 3 weeks for 6 cycles (arm A)
Study: 19273704
Drug: Doxorubicin 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 30 mg/m² per day for 3 consecutive days every 2 weeks for 3 cycles followed by ifosfamide 12.5 g/m² over 5 days every 3 weeks for 3 cycles (arm B)
Study: 19273704
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard-dose doxorubicin)
Study: 11552108
Drug: Warmed intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed intravenous fluids (IVF)
Study: 11552108
Drug: Nonwarmed intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonwarmed intravenous fluids
Study: 7867872
Drug: Twice-weekly thyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly thyroxine therapy
Study: 7867872
Drug: Daily thyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily thyroxine therapy
Study: 334212
Drug: Fenfluramine, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine, 120 mg daily
Study: 19375948
Drug: Partial-breast irradiation
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial-breast irradiation (intraoperative radiation therapy)
Study: 19375948
Drug: Whole-breast radiation
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-breast radiation therapy
Study: 14693787
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam irradiation with five fractions of 3 Gy (total dose 15 Gy)
Study: 14693787
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam irradiation with seven fractions of 2 Gy (total dose 14 Gy)
Study: 11452166
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (600 IU/kg) plus oral iron (n = 29)
Study: 11452166
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus oral iron (n = 27)
Study: 9635707
Drug: Pelvic radiotherapy
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic radiotherapy and bolus 5-fluorouracil-based chemotherapy
Study: 7977118
Drug: Intravenous diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diltiazem (0.25 mg/kg over 2 minutes, followed by 0.35 mg/kg if needed)
Study: 7977118
Drug: Open-label intravenous
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label intravenous diltiazem after placebo
Study: 2698566
Drug: Diltiazem 90
Normalized name: diltiazem 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 90 mg
Study: 30940760
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (WHO recommended first-line treatment)
Study: 26882608
Drug: Jinying Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinying Capsule (JC), 0.5 g per capsule, 4 capsules each time, 3 times per day for 4 weeks
Study: 26882608
Drug: Kangfuyan Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangfuyan Capsule (KC), 0.4 g per capsule, 3 capsules each time, twice per day for 4 weeks
Study: 26882608
Drug: Jinying Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinying Capsule (JC)
Study: 26882608
Drug: Kangfuyan Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangfuyan Capsule (KC)
Study: 21221982
Drug: Clomiphene citrate/gonadotropin/antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene citrate/gonadotropin/antagonist (mild protocol)
Study: 21221982
Drug: Microdose GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microdose GnRH agonist flare (group II)
Study: 12635578
Drug: Topical nasal
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nasal fluticasone (50 micrograms per spray, 2 sprays each side every day)
Study: 12635578
Drug: Topical nasal
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nasal fluticasone
Study: 8311273
Drug: General Anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Anesthesia (GA) with high dose of opioid anesthetic, n = 12
Study: 26317629
Drug: Preoperative Oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative Oral Carbohydrate (CHO)
Study: 26317629
Drug: Preoperative Oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative Oral Rehydration Solution (ORS)
Study: 18077730
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg every 12 hours for 14 days
Study: 18077730
Drug: Midazolam 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 2.0 mg
Study: 12589525
Drug: Caffeinated drink
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeinated drink (100 mg caffeine)
Study: 10880013
Drug: Adenoviral vector
Normalized name: Adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12
DrugBank: Ad-RTS-hIL-12 (DB17177)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenoviral vector delivered intraperitoneally (i.p.) at varying doses (2 x 10(10) to 2 x 10(13) vector particles) with concomitant topotecan chemotherapy and acyclovir.
Study: 27003457
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid administration
Study: 8252937
Drug: Amrinone (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone (1.5 mg/kg loading dose plus 10 micrograms/kg/min maintenance infusion; n = 20)
Study: 3828182
Drug: Extradural infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extradural infusion of 0.125% bupivacaine (Marcain) 10 ml (12.5 mg) per hour during labour
Study: 3828182
Drug: Extradural infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extradural infusion of 0.125% bupivacaine (Marcain)
Study: 26538631
Drug: Urine L-FABP
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urine L-FABP
Study: 18199022
Drug: diclofenac sodium,
Normalized name: diclofenac sodium, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac sodium, 50 mg (taken orally, 3 times per day)
Study: 15728371
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of transgenic potatoes (100 g of tuber, HBsAg at approximately 8.5 microg/g)
Study: 15728371
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of transgenic potatoes (100 g of tuber, HBsAg at approximately 8.5 microg/g)
Study: 12947369
Drug: Pyridostigmine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (30 mg orally 3 times daily for 2 days)
Study: 6649975
Drug: Intravenous Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Metronidazole
Study: 6649975
Drug: Intravenous Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Metronidazole combined with intravenous Gentamycin
Study: 31321427
Drug: Medication cost
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication cost transparency alerts for high-cost medications
Study: 28139972
Drug: AR-C124910XX 60
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR-C124910XX 60 mg twice daily
Study: 28139972
Drug: AR-C124910XX 90
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR-C124910XX 90 mg twice daily
Study: 22848766
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg praziquantel (PZQ)
Study: 22848766
Drug: 75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/kg praziquantel (PZQ)
Study: 20673554
Drug: Adjunctive armodafinil
Normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive armodafinil 150 mg/d
Study: 16337461
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray 200 microg twice daily
Study: 16337461
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray 200 microg once daily
Study: 16337461
Drug: Amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 500 mg 3 times daily
Study: 14988337
Drug: Intravenous adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous adrenaline (epinephrine)
Study: 12520835
Drug: High-dose adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adrenaline
Study: 2794177
Drug: Structural family
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structural family therapy
Study: 2794177
Drug: Psychodynamic child
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic child therapy
Study: 117789
Drug: Oral (Milk)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (Milk) feeding
Study: 31522922
Drug: Subsidized community-supported
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subsidized community-supported agriculture membership (weekly farm produce pickup from June to November)
Study: 25851629
Drug: CYT107 before
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYT107 before chemotherapy
Study: 25851629
Drug: CYT107 during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYT107 during chemotherapy
Study: 25851629
Drug: Placebo before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo before chemotherapy
Study: 25851629
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during chemotherapy
Study: 23547623
Drug: Oral carbohydrate
Normalized name: omega-3 carboxylic acids Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbohydrate solution (CHO) given in the evening prior to surgery and 2-3 hours before anesthesia.
Study: 11386854
Drug: 5-hydroxytryptophan (4-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxytryptophan (4-6 mg/kg) and carbidopa (0.5-1.0 mg/kg)
Study: 11386854
Drug: l-tryptophan (50-70
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-tryptophan (50-70 mg/kg)
Study: 11386854
Drug: 5-hydroxytryptophan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxytryptophan (1 mg/kg)
Study: 8273320
Drug: Dulcolax suppository
Normalized name: bisacodyl Rectal Suppository [Dulcolax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulcolax suppository
Study: 24768116
Drug: COP velocity
Normalized name: COP 1
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COP velocity and ML displacement
Study: 22343600
Drug: Pressure-relieving suspension
Normalized name: LidoPro Pain Relieving Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure-relieving suspension boot (Heelift; DM Systems Inc, Evanston, Illinois)
Study: 22343600
Drug: Intravenous bags
Normalized name: BAG
DrugBank: Ginger (DB10344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bags
Study: 16767414
Drug: Pergolide (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide (0.075 mg)
Study: 10955373
Drug: NK-104 2
Normalized name: NK Cells
DrugBank: Natural Killer Cell (DB15721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK-104 2 mg/day
Study: 10955373
Drug: NK-104 4
Normalized name: NK Cells
DrugBank: Natural Killer Cell (DB15721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK-104 4 mg/day
Study: 8617706
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg/day titrated to 200 mg/day
Study: 26987818
Drug: Behavioural change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural change programme (BCP) with ongoing active reinforcement and enhanced provision of moisturising cream
Study: 15361263
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg fluoxetine for 8 weeks
Study: 10362441
Drug: Metrifonate 50
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate 50 mg once daily
Study: 8808221
Drug: 1.75 mmol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.75 mmol/l calcium dialysate
Study: 8808221
Drug: 1.25 mmol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mmol/l calcium dialysate
Study: 2020143
Drug: Cardioplegic solution
Normalized name: cardioplegic solution no.2
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardioplegic solution (Bretschneider) in Group A
Study: 26683683
Drug: Blinatumomab (9-μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab (9-μg/day continuous i.v. infusion on days 1-7 and 28-μg/day continuous i.v. infusion on days 8-28 for Cycle 1; subsequent cycles 28-μg/day continuous i.v. infusion on days 1-28)
Study: 25054594
Drug: Weekly interdisciplinary
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly interdisciplinary program (WIP) consisting of educational activities, physical therapy, stretching, ergonomics, posture guidance, cognitive behavioral strategies.
Study: 22209391
Drug: Everolimus 10mg
Normalized name: EVEROLIMUS 10MG TAB
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 10mg once daily (1 previous VEGFr-TKI)
Study: 22209391
Drug: Everolimus 10mg
Normalized name: EVEROLIMUS 10MG TAB
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 10mg once daily (2 previous VEGFr-TKI)
Study: 15507793
Drug: Intranasal calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal calcitonin daily for 6 weeks
Study: 7917695
Drug: Prophylactic medication
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic medication (pirenzepine)
Study: 7917695
Drug: Prophylactic medication
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic medication (famotidine)
Study: 7917695
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment (either pirenzepine or famotidine)
Study: 7917695
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (first 36 patients without prophylactic medication)
Study: 3126637
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) patch 5 mg/24 hours
Study: 3126637
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) patch 10 mg/24 hours
Study: 28360247
Drug: Thrice weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice weekly aerobic exercise training (AT) for 6 months
Study: 28360247
Drug: Thrice weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice weekly aerobic exercise training (AT)
Study: 19220089
Drug: Intravenous pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pentoxifylline (500 mg in 500 mL saline for 2 hours followed by 700 mg in 1000 mL saline for 6 hours)
Study: 19220089
Drug: Placebo (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1500 mL saline)
Study: 15176496
Drug: Orally inhaled
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally inhaled fluticasone propionate (FP) 88 or 220 microg via metered-dose inhaler (MDI)
Study: 15176496
Drug: Orally inhaled
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally inhaled fluticasone propionate (FP) 250 microg via Diskus
Study: 15176496
Drug: Orally inhaled
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally inhaled fluticasone propionate (FP) 250 microg/salmeterol 50 microg via Diskus
Study: 10404811
Drug: Transdermal 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17beta-estradiol (50 microg) for 6 weeks
Study: 10404811
Drug: Estradiol in
Normalized name: estradiol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol in combination with oral norethisterone (1 mg) for 6 weeks
Study: 10404811
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo patches for 6 weeks
Study: 10404811
Drug: Matching oral
Normalized name: By Ache Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral placebo preparation for 6 weeks
Study: 7564870
Drug: Omeprazole (OM)
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole (OM) 20 mg mane
Study: 7564870
Drug: Ranitidine (RAN)
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine (RAN) 300 mg nocte
Study: 2406538
Drug: Fructose 1,6-diphosphate
Normalized name: fructose 1,6-diphosphate
DrugBank: Fosfructose (DB13863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose 1,6-diphosphate (FDP) infusion (250 mg.kg-1 body weight)
Study: 6111083
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg pindolol combined with 5 mg clopamide
Study: 6111083
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg metoprolol combined with 12.5 mg hydrochlorothiazide
Study: 31986288
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium chloride (KCl) infusion at rates of 9.4 mmol/h, 12 mmol/h, or 15 mmol/h
Study: 28587952
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) 60mg loading dose at admission, followed by 20mg three times a day
Study: 27354782
Drug: Glycopyrrolate 15.6
Normalized name: GLYCOPYRROLATE 15.6MCG CAP,INHL,60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 15.6 µg
Study: 21733320
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg cholecalciferol per day
Study: 17852442
Drug: Alternating therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating therapy with DFP at 75 mg/kg/day for 4 days/week and DFO at 40 mg/kg/day for 5-7 nights/week
Study: 17852442
Drug: Alternating therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating therapy with DFP and DFO
Study: 15024929
Drug: Observed single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observed single low-dose mefloquine (15 mg/kg) and artesunate (4 mg/kg)
Study: 15024929
Drug: Observed single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observed single high-dose mefloquine (25 mg/kg) and artesunate (4 mg/kg)